Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 1218-1224, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Calhoun, E. S.
Right arrow Articles by Persing, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Calhoun, E. S.
Right arrow Articles by Persing, D. H.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Cancer Diagnostics (since 2002)
(Clinical Chemistry. 2002;48:1218-1224.)
© 2002 American Association for Clinical Chemistry, Inc.

Host Genetic Polymorphism Analysis in Cervical Cancer

Eric S. Calhoun1, Renee M. McGovern1, Carol A. Janney1, James R. Cerhan1, Stephen J. Iturria1, David I. Smith1, Bobbie S. Gostout1 and David H. Persing2,3a

1 Mayo Foundation for Medical Education and Research, Rochester, MN 55905.

2 Corixa Corporation and the
3 Infectious Disease Research Institute, Seattle, WA 98104.

aAddress correspondence to this author at: Corixa Corporation, Seattle Life Sciences Center, Suite 200, 1124 Columbia St., Seattle, WA 98104. Fax 206-754-5715; e-mail PERSING{at}CORIXA.com.

Background: The natural history of cervical cancer comprises a latency period that probably involves long-term immunologic tolerance of human papillomavirus infection. Identifying host determinants of viral persistence may help to better understand the mechanisms of tolerance and may lead to the development of tests that can allow more focused follow-up of high-risk individuals.

Methods: Genotypic frequencies of 12 polymorphic loci in four candidate genes from 127 cervical cancer patients were compared with a control group of 108 female blood donors. Genotypes were determined by PCR amplification and direct sequencing of isolated genomic DNA.

Results: The tumor necrosis factor-{alpha} (TNF{alpha}) -238 polymorphism was significantly underrepresented in cervical cancer patients [heterozygotes (HETs), odds ratio (OR) = 0.33; 95% confidence interval (CI), 0.11–0.96], as was the TNF{alpha} -376 polymorphism (P = 0.02; 0% for any variant genotype in cases vs 4.7% in controls). The NRAMP1 3' untranslated region STP+86 polymorphism also appeared to be inversely associated with cervical cancer, but this result did not reach statistical significance (HET, OR = 0.57; 95% CI, 0.32–1.02). The p53 codon 72 arginine allele showed a suggestive negative association with cervical cancer (HET, OR = 0.49; 95% CI, 0.14–1.63; homozygotes, OR = 0.35; 95% CI, 0.11–1.17). The remaining alleles tested showed no association with cervical cancer.

Conclusions: We identified host genetic polymorphisms that may be associated with cervical cancer risk, some of which have been linked to potential functional effects on cellular immune responses or antigen processing. We failed to confirm earlier reports of increased cervical cancer susceptibility in women who harbor the p53 P72R allele. Although our findings support the general hypothesis that host immunogenetic determinants other than class II MHC may be important in the development of cervical cancer, further analysis of the HLA gene cluster comprising the implicated TNF{alpha} single-nucleotide polymorphisms will be required to determine whether their association is linkage independent.




The following articles in journals at HighWire Press have cited this article:


Home page
 Hum Mol GenetHome page
V. B. Guzman, A. Yambartsev, A. Goncalves-Primo, I. D.C.G. Silva, C. R.N. Carvalho, J. C.L. Ribalta, L. R. Goulart, N. Shulzhenko, M. Gerbase-DeLima, and A. Morgun
New approach reveals CD28 and IFNG gene interaction in the susceptibility to cervical cancer
Hum. Mol. Genet., June 15, 2008; 17(12): 1838 - 1844.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
T.-H. Su, T.-Y. Chang, Y.-J. Lee, C.-K. Chen, H.-F. Liu, C.-C. Chu, M. Lin, P.-T. Wang, W.-C. Huang, T.-C. Chen, et al.
CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women
Carcinogenesis, June 1, 2007; 28(6): 1237 - 1240.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. Koushik, R. W. Platt, and E. L. Franco
p53 Codon 72 Polymorphism and Cervical Neoplasia: A Meta-Analysis Review
Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 11 - 22.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.